AbbVie's Cariprazine (VRAYLAR) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder

Mount Carmel Register

Oct 29, 2021

AbbVie's Cariprazine (VRAYLAR) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder |!| Mount Carmel